» Articles » PMID: 26560699

Opening Clinical Trial Data: Are the Voluntary Data-sharing Portals Enough?

Overview
Journal BMC Med
Publisher Biomed Central
Specialty General Medicine
Date 2015 Nov 13
PMID 26560699
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Data generated by the numerous clinical trials conducted annually worldwide have the potential to be extremely beneficial to the scientific and patient communities. This potential is well recognized and efforts are being made to encourage the release of raw patient-level data from these trials to the public. The issue of sharing clinical trial data has recently gained attention, with many agreeing that this type of data should be made available for research in a timely manner. The availability of clinical trial data is most important for study reproducibility, meta-analyses, and improvement of study design. There is much discussion in the community over key data sharing issues, including the risks this practice holds. However, one aspect that remains to be adequately addressed is that of the accessibility, quality, and usability of the data being shared. Herein, experiences with the two current major platforms used to store and disseminate clinical trial data are described, discussing the issues encountered and suggesting possible solutions.

Citing Articles

Molecular classification of geriatric breast cancer displays distinct senescent subgroups of prognostic significance.

Wu X, Chen M, Liu K, Wu Y, Feng Y, Fu S Mol Ther Nucleic Acids. 2024; 35(4):102309.

PMID: 39296329 PMC: 11408383. DOI: 10.1016/j.omtn.2024.102309.


Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets.

El Kababji S, Mitsakakis N, Fang X, Beltran-Bless A, Pond G, Vandermeer L JCO Clin Cancer Inform. 2023; 7:e2300116.

PMID: 38011617 PMC: 10703127. DOI: 10.1200/CCI.23.00116.


A method for generating synthetic longitudinal health data.

Mosquera L, El Emam K, Ding L, Sharma V, Zhang X, El Kababji S BMC Med Res Methodol. 2023; 23(1):67.

PMID: 36959532 PMC: 10034254. DOI: 10.1186/s12874-023-01869-w.


Implementation of platform trials in the COVID-19 pandemic: A rapid review.

Vanderbeek A, Bliss J, Yin Z, Yap C Contemp Clin Trials. 2021; 112:106625.

PMID: 34793985 PMC: 8591985. DOI: 10.1016/j.cct.2021.106625.


Development and Validation of a Prediction Model for Elevated Arterial Stiffness in Chinese Patients With Diabetes Using Machine Learning.

Li Q, Xie W, Li L, Wang L, You Q, Chen L Front Physiol. 2021; 12:714195.

PMID: 34497538 PMC: 8419456. DOI: 10.3389/fphys.2021.714195.


References
1.
Milne C, Bruss J . The economics of pediatric formulation development for off-patent drugs. Clin Ther. 2008; 30(11):2133-45. DOI: 10.1016/j.clinthera.2008.11.019. View

2.
Nisen P, Rockhold F . Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med. 2013; 369(5):475-8. DOI: 10.1056/NEJMsr1302541. View

3.
Hede K . Project data sphere to make cancer clinical trial data publicly available. J Natl Cancer Inst. 2013; 105(16):1159-60. DOI: 10.1093/jnci/djt232. View

4.
Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J . ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014; 58(2-3):234-9. DOI: 10.1007/s12026-014-8516-1. View

5.
Rosenblatt M, Jain S, Cahill M . Sharing of clinical trial data: benefits, risks, and uniform principles. Ann Intern Med. 2015; 162(4):306-7. DOI: 10.7326/M14-1299. View